Objective To evaluate the adherence to oral cavity quality guidelines endorsed by the American Head and Neck Society (AHNS) at a large tertiary care hospital. Methods This retrospective study identified patients treated for early‐stage oral tongue squamous cell carcinoma at a tertiary care hospital from 1992 to 2013. Patient charts were reviewed for 26 process quality measures and four key indicator process quality measures as endorsed by the AHNS. Patients were then grouped by diagnosis date either before (historical group, 1992–2007) or after (current treatment group, 2008–2013) the published process quality measures from the AHNS. Descriptive statistics were used to evaluate the rates of adherence for each process quality measure within the 2 groups. Results Of the 57 patients identified, 29 were female (51%). The mean age was 62.3 years. A majority of the oral cavity cancers were stage I (59.6%), followed by stage II (35.1%) and stage III (5.3%). Compliance with the process quality measures was in the acceptable range in both cohorts. However, several areas demonstrated lower adherence in both cohorts. Statistically significant improvements were noted between the two cohorts, which showed a measurable improvement in adherence to process quality measures in several key areas over time. Conclusion Using the process quality measures proposed by the AHNS, adherence to the process quality measures for early‐stage oral cavity cancer care at a tertiary care center was successfully evaluated. In general, good compliance with the proposed process quality measures was found and several areas for improvement were identified. Level of Evidence 2c Laryngoscope, 129:1816–1821, 2019

Category: Midfoot/Forefoot; Other Introduction/Purpose: Hallux Rigidus (HR) can cause pain with motion, enlarged joint, decreased joint space, subchondral sclerosis, osteophyte formation and restricted joint mobility, limiting patient physical activity. A modern technique for the treatment of HR is 1st MTP hemiarthroplasty with the use of a Cartiva synthetic cartilage implant. The Cartiva implant is designed to imitate natural cartilage; this allows patients to maintain motion in the 1st MTP joint. Current scientific literature reporting early outcomes of the procedure is sparse and mixed. This discrepancy and the overall scarcity of data indicates the need for further analysis. The purpose of this study is to compare improvement in VAS with 1st MTP hemiarthroplasty with the Cartiva implant, allograft interposition arthroplasty and fusion in patients who failed conservative management or cheilectomy. Methods: This study evaluated subjects who underwent interpositional arthroplasty, arthrodesis, or hemiarthroplasty with the Cartiva implant from January 2008 to April 2020, with a minimum of one year documented follow-up. All subjects were 18 years of age and older, diagnosed Hallux rigidus with pain, had a decrease in 1st MTP motion, and had X-ray findings consistent with decreased joint space. Patient data collected includes age, gender, ethnicity, occupation, height, weight, BMI, diabetes status, rheumatoid arthritis status, smoking, co-morbid conditions, medication, activity of choice, duration of symptoms, and operative data. Pre-operative and post- operative Visual Analog Scale (VAS) pain scores were compared between groups. Pain, function, and alignment between groups were also evaluated, pre-operatively and post- operatively, using the AOFAS Midfoot Scale. Secondary objectives evaluated include surgical complications, surgical revision, and X-rays. Results: One hundred patients with 12 months of post-operative follow-up were included in this study: 52 hemiarthroplasty with Cartiva implant patients (Group A), 24 arthrodesis patients (Group B), and 24 interpositional arthroplasty patients (Group C). The mean age of patients was 57.12 years (range 35-95). Average VAS pain scores for Group A was 3.78 (0-9), for Group B was 2.71 (0-10), and Group C was 3.67 (0-8). The average AOFAS score for Group A was 63.36 (30-95), for Group B was 60.98 (32- 83), and Group C was 60.13 (31-83). Pre-operative average VAS pain scores were 4.86 (Group A), 2.32 (Group B), and 5.58 (Group C). Post-operative average VAS pain scores were 2.69 (Group A), 0.91 (Group B), and 1.75 (Group C). Pre-operative average AOFAS scores were 59.52 (Group A), 48 (Group B), and 47.25 (Group C). Post-operative average AOFAS scores were 67.20 (Group A), 73.96 (Group B), and 73 (Group C). Conclusion: Preliminary data shows the greatest reduction in VAS pain scores in the interpositional arthroplasty group. The greatest improvement in derived AOFAS score was seen in the arthrodesis and interpositional arthroplasty groups, indicating a better overall combination of post-operative pain, function, and alignment when compared to patients who underwent hemiarthroplasty with Cartiva implant. While this study is not yet complete, it appears that hemiarthroplasty with Cartiva implant may allow patients to maintain motion in the 1st MTP joint, but at the cost of increased post-operative pain.

Background: Inflammatory cells such as tumor infiltrating lymphocytes (comprising T and B cells) are often present in prostate tissue undergoing tumorigenesis but their role in disease progression is unclear. The current study aims to characterize the expression dynamics of CD3, CD4 and CD20 lymphocytes from the pre- to post-malignant prostate environment and the association of these dynamics with aggressive prostate cancer. Methods: The study sample included 72 prostate cancer cases (44 whites and 28 African American) that underwent surgery as their primary treatment and had a benign prostate biopsy at least one year before diagnosis and were followed for biochemical recurrence (BCR). Counts of CD3-, CD4- and CD20-positive lymphocytes were quantified by immunohistochemistry using an automated multi-image processing procedure in pre-malignant benign biopsy (BB), tumor-adjacent benign (TAB) and malignant tumor glandular (MTG) regions of prostatectomy. A cox proportional hazards model was used to estimate the hazard ratio (HR) of time to BCR associated with inflammatory marker count in different regions of the prostate. Clustering was performed to identify similar trends of expression changes of CD3, CD4 and CD20 between the regions - BB, TAG and MTG using Time-series Anytime Density Peaks Clustering (TADPole). Results: The risk of BCR was significantly reduced in men who had an elevated CD20 count in the TAG (HR=0.80, p=0.01) after adjusting for race, age at diagnosis, PSA at the time of benign biopsy and the Gleason grade group. CD3 and CD4 counts in the prostate regions did not show any significant association to BCR. TADPole identified four main different patterns of CD20 expression changes across the BB-TAB-MTG regions namely 1) minimal to no change in expression between the regions (n=45 pairs); 2) high expression in BB/no expression in TAG/higher expression in MTG (n=3 pairs); 3) high expression in BB/higher expression in TAG/no expression in MTG (n=8 pairs); 4) no expression in BB/higher expression in TAG compared to MTG (n=16 pairs). In comparison to the reference group (Cluster 1), Cluster 4 was at 3.5 times higher risk of BCR with an adjusted HR of 3.5 (p=0.0184). Conclusion: Elevated CD20 expression in TAG was associated with less aggressive disease. Furthermore, cases that had CD20 expression highest in their benign prostate adjacent to tumor preceded by absence of CD20 expression in their pre-malignant benign prostate had the most aggressive disease course. Further studies are warranted to understand how CD20 lymphocyte dynamic changes influence prostate tumorigenesis. Citation Format: Sudha M. Sadasivan, Yalei Chen, Nilesh S. Gupta, Ryan Sanii, Kevin R. Bobbitt, Dhananjay A. Chitale, Sean R. Williamson, Andrew G. Rundle, Deliang Tang, Benjamin A. Rybicki. Change in B cell lymphocyte expression from the pre- to post-malignant prostate predicts disease aggressiveness [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 80.